Resumen: Los resultados del ensayo fundamental frontMIND fase 3 de la combinación tafasitamab (Monjuvi®/Minjuvi®) de Incyte presentados en el plenario del Congreso de la Asociación Europea de Hematología (EHA) 2026...

Key Takeaway: The article discusses the presentation of phase 3 trial results for tafasitamab at the European Hematology Association Congress 2026. However, specific details about the results or implications are not provided in the text. The focus appears to be on the event rather than the findings themselves.